Androgen supplementation in women has received enormous attention in the scientific and lay communities. That it enhances some aspects of cognitive function, sexual function, muscle mass, strength, and sense of well-being is not in question. What is not known is whether physiological testosterone replacement can improve health-related outcome in older women without its virilizing side effects. Although it is assumed that the testosterone dose-response relationship is different in women than in men and that clinically relevant outcomes on the above-mentioned effects can be achieved at lower testosterone doses, these assumptions have not been tested rigorously. Androgen deficiency has no clear-cut definition. Clinical features may include impaired sexual function, low energy, depression, and a total testosterone level of less than 15 ng/dL, the lower end of the normal range. Measurement of free testosterone is ideal, because it provides a better estimate of the biologically relevant fraction. It is not widely used in clinical practice, because some methods of measuring free testosterone assay are hampered by methodological difficulties. In marked contrast to the abrupt decline in estrogen and progesterone production at menopause, serum testosterone is lower in older women than in menstruating women, with the decline becoming apparent a decade before menopause. This article reviews testosterone's effects on sexual function, cognitive function, muscle mass, body composition, and immune function in postmenopausal women. J Am Geriatr Soc 50:1131-1140, 2002. Key words: androgen; menopausal women; cognitive; sexual; muscle mass; bone density T hat testosterone supplementation might improve some aspects of cognitive and sexual functions, muscle mass and strength, bone mineral density, and sense of well-being is not in question, but it is not known whether physiological testosterone replacement can induce clinically meaningful improvements in health-related outcomes in older women without its limiting, virilizing side effects. It has been assumed that testosterone dose-response relationships are different in women than in men and that clinically significant effects on psychosexual function, body composition, physical function, bone mineral density, and other health-related outcomes can be achieved at testosterone doses and concentrations that are substantially lower than those required to produce similar effects in men. Neither of these assumptions has been tested rigorously. Furthermore, the premise that the organ systems that are the targets of virilizing side effects, such as the skin, hair, vocal cords, and clitoris, differ from muscle and bone in their testosterone sensitivity remains unsubstantiated. The clinical applications of testosterone in women are critically predicated upon the postulate that, by appropriate selection of testosterone dose, clinically beneficial effects can be dissociated from virilizing side effects.
T hat testosterone supplementation might improve some aspects of cognitive and sexual functions, muscle mass and strength, bone mineral density, and sense of well-being is not in question, but it is not known whether physiological testosterone replacement can induce clinically meaningful improvements in health-related outcomes in older women without its limiting, virilizing side effects. It has been assumed that testosterone dose-response relationships are different in women than in men and that clinically significant effects on psychosexual function, body composition, physical function, bone mineral density, and other health-related outcomes can be achieved at testosterone doses and concentrations that are substantially lower than those required to produce similar effects in men. Neither of these assumptions has been tested rigorously. Furthermore, the premise that the organ systems that are the targets of virilizing side effects, such as the skin, hair, vocal cords, and clitoris, differ from muscle and bone in their testosterone sensitivity remains unsubstantiated. The clinical applications of testosterone in women are critically predicated upon the postulate that, by appropriate selection of testosterone dose, clinically beneficial effects can be dissociated from virilizing side effects.
There is enormous public interest in and media fascination with the issue of androgen supplementation in women. For instance, in 2000, stories related to this topic appeared in many major U.S. newspapers and on the Oprah Winfrey show and other television network programs in the United States, Australia, and Europe. The number of stories appearing in the lay press in the past 2 years has far exceeded the number of randomized clinical trials.
In spite of the growing media attention, the issue of androgen supplementation in women has remained controversial in the scientific community. Many uncertainties have contributed to a lack of consensus. The commercially available assays for total and free testosterone were developed for the measurements of much higher circulating concentrations in men; these assays have generally lacked the sensitivity and precision required to accurately measure the lower levels of testosterone in older women. 1 There has been a paucity of normative data on testosterone levels in menstruating women, older women, and women with chronic illnesses; this has made it difficult to define androgen deficiency in women in precise quantitative terms. The available formulations for androgen administration were developed for the replacement of the much higher doses required for the treatment of hypogonadal men. Few pharmacokinetic data exist on the bioavailability and clearance of androgens delivered from the available formulations in women. Therefore, it is not surprising that many previous clinical studies in women used pharmacological doses of testosterone in relatively unphysiological experimental paradigms. The objective of physiological testosterone replacement is to restore serum total and free testosterone concentrations to a range that is mid-normal to high normal for healthy younger women. Testosterone regimens that increase serum testosterone levels into the supraphysiological range should be viewed as pharmacological.
Sexual dysfunction in women, a highly complex, multifactorial issue, has become synonymous with androgen deficiency in the lay press. Observations that pharmacological doses of testosterone might improve sexual function in subsets of women with sexual dysfunction have been unjustifiably extrapolated to advocate testosterone replacement as a general treatment for sexual dysfunction in older women.
It would be incorrect to assert that testosterone supplementation of older women has no role in clinical practice, but the available data do not warrant a general recommendation for testosterone replacement for all postmenopausal women. Table 1 lists the adrenal androgens and their potencies and concentrations in serum for premenopausal and postmenopausal women.
BIOLOGY OF TESTOSTERONE PRODUCTION IN MENSTRUATING, POSTMENOPAUSAL, AND OLDER WOMEN
Adrenal and ovarian production of androgens in healthy younger menstruating women collectively contributes to secretion of approximately 300 g testosterone daily into the general circulation. 2 Approximately half of the circulating testosterone is derived from ovarian secretion. 3 The adrenal gland produces testosterone precursors dehydroepiandrosterone (DHEA), dehydroepiandrosterone sulfate (DHEAS), and androstenedione, whose peripheral conversion to testosterone contributes the other half of circulating testosterone. 4 Although the current dogma assumes approximately equal contribution from the ovaries and the adrenal glands, these assumptions may not be entirely correct. The data from studies in which testosterone production rates were measured after suppression of the hypothalamic-pituitary-adrenal axis with dexamethasone administration are suspect because dexamethasone is known also to suppress ovarian steroidogenesis. DHEAS is secreted entirely from the adrenal gland, whereas the adrenal glands and the ovaries secrete DHEA. The majority of circulating DHEA is derived from peripheral conversion of DHEAS. In women of all ages, the metabolism of DHEA and DHEAS into bioactive sex steroids may occur in many tissues, including adipose, bone, muscle, prostate, and breast tissue and the skin, the brain, the ovary, the testes, and the liver. DHEA and DHEAS are enzymatically converted to testosterone and then to DHT in the adrenal glands, ovaries, and other peripheral tissues. Circulating androstenedione is derived from secretion by zona fasciculata of the adrenal glands and stromal cells within the ovaries.
Androgen Levels During The Menstrual Period
In regularly ovulating women, plasma levels of testosterone and androstenedione rise gradually during the follicular phase to reach their highest levels in the preovulatory phase, with a second rise in androstenedione during the late luteal phase. 1, 5 Serum testosterone concentrations during the mid-follicular phase are not significantly different from those in mid-luteal phase. 1 Ovariectomy causes a drop in serum testosterone and androstenedione by about 50% each. 6 Changes In Androgen Levels with Menopause and Aging Serum testosterone levels are lower in older women than in younger menstruating women. The decline in DHEAS and testosterone becomes apparent in the decade before menopause and is gradual and progressive 7 such that the testosterone level of women in their 60s is about 50% that of women in their 20s. 8 This is in contrast to the dramatic decline in estradiol and progesterone production that occurs at menopause. The progressive decline of DHEAS and testosterone with age is independent of the menopausal transition. 8 Although some studies have reported a decrease in androstenedione concentrations during menopause, 9 a large cross-sectional epidemiological study in Australia reported no significant change in serum total testosterone concentrations in the perimenopausal period, demonstrating that the ovarian androgen secretion is not attenuated in most women at menopause. 10 It has been reported that some ovaries may undergo stromal hyperplasia under the control of elevated gonadotropins 9 and produce even higher amounts of androgens than they produced before menopause. Nevertheless, on average, testosterone production continues to decrease gradually after the fourth decade. 11
Testosterone Metabolism
Testosterone serves not only as an androgenic hormone, but also as a prohormone; it is converted in the periphery into two active metabolites, estradiol and dihydrotestosterone (DHT). Testosterone's effects on the skin require its obligatory 5-␣ -reduction to dihydrotestosterone. 12 In contrast, testosterone's effects on bone resorption, gonadotropin suppression, plasma lipids, brain organization, and some aspects of cognitive function require its aromatization to estradiol. 13 We do not know whether 5-␣ -reduction of testosterone to DHT is obligatory for mediating its effects on the muscle and cortical bone formation. Labrie et al. 14 have suggested that serum concentrations of testosterone and DHT may underestimate total androgenic activity and that conjugated metabolites of DHT and testosterone, such as androsterone glucuronide, androstane-3 ␣ ,17 ␤ -diol-glucuronide, androstane-3 ␤ ,17 ␤ -diol-glucuronide and androsterone-sulfate, may be more reliable markers of the androgen action at the end organ. 15, 16 We do not know whether measurement of 3-␣ androstanediol glucuronide would provide a better marker of androgen action than serum levels of total and free testosterone.
MEASUREMENT OF TOTAL AND UNBOUND TESTOSTERONE
In healthy women, approximately 50% to 60% of testosterone is bound to sex hormone binding globulin (SHBG) and 30% to 40% to albumin; only 0.5% to 3% is unbound. The free hormone hypothesis assumes that only the free and loosely bound (testosterone bound to albumin) exerts biologic effects. 17 Many factors affect SHBG; thyroid hormone, estrogen, and aging increase it and testosterone, glucocorticoids, growth hormone, and insulin decrease it. 18 Although measurements of unbound testosterone should provide a better estimate of the biologically relevant fraction, in practice, some measurements of free and bioavailable testosterone have been hampered by methodological difficulties, particularly in women. The commercially available assays for the measurement of unbound testosterone include the equilibrium dialysis method, the bioavailable testosterone by the ammonium sulfate precipitation method, free testosterone indices calculated from the measured total testosterone and SHBG concentrations, and tracer analog methods for estimates of free testosterone. Of these methods, the equilibrium dialysis method for the measurement of unbound testosterone and the ammonium sulfate precipitation method for the measurement of albumin-bound and unbound testosterone (bioavailable testosterone) are acceptable methods that have good clinical correlation and are accurate, independent from the effects of SHBG concentrations, and available at specialized commercial endocrinology laboratories. The estimates of free testosterone, calculated from total testosterone and SHBG concentrations, have also been shown to correlate with free testosterone concentrations measured by dialysis in men. These algorithms have not been extensively tested in women. 19 Tracer analog methods of measuring free testosterone are widely available but are affected by SHBG concentrations and do not provide an accurate measure of unbound testosterone 19 and are not recommended. A recent commentary by Rosner emphasized that direct radioimmunoassay of free testosterone by the tracer analog method may underestimate its concentration. 20 
ANDROGEN DEFICIENCY STATES IN WOMEN
There is no consensus on a clinical or biochemical definition of androgen deficiency in women. A physical and behavioral symptom complex termed "female androgen deficiency syndrome" includes impaired sexual function, loss of energy, and depression. 21 Based on the distribution of serum total and free testosterone concentrations in healthy menstruating women, androgen deficiency could be defined by serum total testosterone concentrations less than 15 ng/dl, the lower end of the normal female range. 1 The causes of androgen deficiency in women can be divided into ovarian, adrenal, central, and systemic causes. Ovarian causes include premature ovarian failure, Turner's syndrome, and surgical or chemical ovariectomy. Gonadal dysgenesis; streak gonads; estrogen deficiency; and low circulating levels of androstenedione, testosterone, free testosterone, and SHBG characterize Turner's syndrome. 22 Most of these women are receiving estrogen and progesterone replacement, which further decreases their free androgen levels by increasing the SHBG concentrations; in addition, luteinizing hormone suppression by hormone replacement therapy (HRT) may further decrease the stimulus for ovarian androgen production. 19 It is possible that the reduction in free androgen levels induced by traditional HRT might adversely affect sexual function in postmenopausal women.
Primary adrenal insufficiency is associated with deficiencies of glucocorticoids and adrenal androgens. Central causes of androgen deficiency include disorders affecting the pituitary or the hypothalamus. Panhypopituitarism affects androgen secretion from adrenal and ovarian sources; not surprisingly, patients with panhypopituitarism have lower circulating concentrations of total and free testosterone and androstenedione than those found in patients with adrenal or ovarian failure alone. 23 Gonadotropin-releasing hormone agonist or antagonist analogs, often used for treating endometriosis and other reproductive disorders, suppress gonadotropin secretion. Glucocorticoid therapy suppresses corticotropin-releasing hormone and adrenocorticotropic hormone and leads to low levels of cortisol, DHEA, DHEAS, and androstenedione. 24 In addition, pharmacological doses of glucocorticoids in amounts greater than 10 mg of prednisone daily or equivalent doses of other glucocorticoids directly inhibit ovarian steroidogenesis. 25 Human immunodeficiency virus (HIV) infection and chronic illness are examples of systemic causes of androgen deficiency. Table 2 summarizes the effects of testosterone administration on sexual function. The prevalent dogma is that androgens regulate libido in women, although a woman's sexual behavior is greatly affected by environmental, emotional, cultural, and hormonal factors. 21 The effects of androgens in the brain are mediated directly through the androgen receptor and through aromatization of testosterone to estradiol. Androgen receptors have been identified in the cortex, pituitary, hypo-thalamus, preoptic region, thalamus, amygdala, and brainstem. 26 Testosterone supplementation is associated with increased well-being, energy, appetite, and improved somatic and psychological scores in surgically menopausal women. 27 For instance, in one study of surgically menopausal women, supraphysiological doses of testosterone enanthate alone or in combination with estrogen increased sexual desire, fantasies, and arousal more than estrogen alone. 28 In another study, testosterone and estradiol implants increased sexual activity, satisfaction, pleasure, and frequency of orgasm more than estrogen implants alone. 29 In a recent, well-designed, placebo-controlled randomized clinical trial, women who underwent hysterectomy and ovariectomy and were on estrogen replacement were randomized to placebo patches or testosterone patches designed to nominally deliver 150 and 300 g of testosterone daily for 12 weeks each. Although both dose-regimens of testosterone significantly increased serum testosterone levels, only the higher dose, which increased mean serum free testosterone levels into the upper end of the normal female range, was associated with improvements in frequency of sexual activity, pleasure, orgasm, sexual fantasies, masturbation, and positive well-being. 30 Tutten et al. reported that oral administration of testosterone undecenoate increased vaginal vasocongestion as measured by vaginal plethysmography during exposure to a potent visual stimulus in a small number of women with hypothalamic amenorrhea. 29 In a placebo-controlled crossover study, daily administration of 50 mg DHEA daily for 4 months in women with adrenal insufficiency improved several aspects of sexual function and sense of well-being. It is unclear whether these effects were direct effects of DHEA on the brain or indirect effects due to the conversion of DHEA to testosterone. 31 In contrast, a cross-sectional study did not show a correlation between sexual function and gonadal steroids. 32 Thus, it appears likely that supraphysiological doses of testosterone that increase serum testosterone levels above the physiological range for healthy younger women may improve some aspects of sexual function in a subset of women with low androgen levels, but we do not know whether physiological replacement doses that increase serum testosterone levels into the mid-range for younger menstruating women would produce meaningful improvements in sexual function and activity in healthy older women with low testosterone levels.
TESTOSTERONE AND SEXUAL FUNCTION

EFFECTS OF TESTOSTERONE ADMINISTRATION ON BODY COMPOSITION, MUSCLE PERFORMANCE, AND PHYSICAL FUNCTION
There is agreement that testosterone administration to men is associated with a dose-and concentration-dependent increase in fat-free mass, muscle size, and maximal voluntary strength and a decrease in fat mass. [33] [34] [35] [36] [37] [38] The data on the effects of testosterone administration in women are far more limited. Total lean mass and lean leg mass are significantly correlated with free but not total testosterone levels in postmenopausal women aged 46 to 55. 39 One cross-sectional study showed that testosterone level predicted muscle strength in postmenopausal women. 40 Estrogen therapy in postmenopausal women, by lowering free testosterone concentrations, can accelerate the loss of lean body mass. 39 The data on the anabolic effects of testosterone in women are limited. Kenyon et al. reported significant nitrogen retention with administration of pharmacological doses of testosterone propionate to healthy menstruating women. 41 In a more recent study, combined administration of testosterone and estrogen implants increased lean body mass and decreased body fat more than estrogen implants alone. 42 In a placebo-controlled study of HIV-infected women with weight loss, testosterone supplementation by means of transdermal testosterone patches, designed to nominally deliver 150 or 300 g of testosterone daily, was not associated with significant gains in lean body mass or muscle strength at either testosterone dose (Table 3) . 43 DHEA administration has been reported to increase fat-free mass in postmenopausal women, 44, 45 but, in another study, DHEA (50 mg/day) given for 4 months to women with adrenal insufficiency did not result in a change in body mass index or waist-hip ratio (Table 3) . 46 Most of the published studies that have examined the effects of androgen supplementation in women have had small sample sizes, few examined the effects on muscle performance and physical function, and none has unequivocally demonstrated improvements in health-related outcomes. Therefore, it remains unclear whether increasing testosterone concentrations in older women with low testosterone levels into the mid-to upper-normal range will be associated with clinically significant gains in fat-free mass, muscle performance or physical function.
TESTOSTERONE AND COGNITIVE FUNCTION
Most of the research on the hormonal contribution to cognitive function has focused on estrogens. The neuroprotective and neurotrophic effects of estrogens are well recognized, but the underlying mechanisms are not well understood. Estrogens interact with nerve growth factor, brain derived neurotrophic factor, insulin-like growth factor-1 (IGF-1), and fibroblast growth factor. [47] [48] [49] [50] [51] Estrogens also act directly on neurotransmitter complexes and ion channels, exhibit antioxidant effects in the brain, reduce neuronal death after exposure to pro-oxidants, and improve cerebral blood flow. [52] [53] [54] Testosterone is aromatized to estradiol in the brain, and some effects of testosterone may be mediated through its conversion to estradiol, but androgen receptors are expressed in specific regions of the brain 55 and likely mediate some of testosterone's organizational effects during brain development and some activational effects postnatally. 56, 57 There are gender differences in the distribution of androgen receptors in the human hypothalamus. 58 The effects of testosterone on cognitive function conflict. Low DHEAS levels in postmenopausal women do not correlate with cognitive decline. 59 It is possible that brain levels rather than plasma hormone levels are important. In another study in older men, there was a positive correlation between testosterone and bioavailable testosterone levels and global cognitive function and mental control but not visual-spatial skills. 60 An investigation of healthy younger adults showed that salivary testosterone was negatively correlated with visual-spatial and verbal cognitive scores in right-handed men and positively correlated in righthanded women in a curvilinear fashion. 61 This pattern was not evident in left-handed individuals.
The effects of androgens on cognitive function are domain specific. For instance, observations that men outperform women in a variety of visual-spatial skills suggest that androgens enhance visual-spatial skills. 62 Janowsky et al. 63 tested verbal and visual memory, spatial cognition, motor speed, and cognitive flexibility in a group of older men who received 3 months of testosterone supplementation. Testosterone replacement was associated with a significant improvement in spatial cognition only. Serum testosterone levels were not significantly correlated with spatial performance, but estradiol levels showed a significant inverse relationship to spatial performance, suggesting that estradiol inhibits spatial ability. A study of San Bushmen 63 showed that testosterone but not estradiol levels correlate with better spatial ability and worse verbal fluency. Circulating levels of dihydrotestosterone, a metabolite of testosterone, are positively correlated with verbal fluency. Barrett-Conner et al. 64 found an association of total and bioavailable testosterone levels with global cognitive functioning and mental control but not with visualspatial skills in older women. Other studies 61, 65, 66 have reported a curvilinear relationship between androgen levels and spatial ability such that women with high testosterone levels and men with low testosterone levels show the best performance. Several small clinical trials of testosterone supplementation and cognition in older hypogonadal men have provided conflicting results. Sih et al. 67 found no effect, whereas other studies 68, 69 reported an effect. Hypogonadal men performed worse on tests of verbal fluency than eugonadal men and showed improvement after testosterone replacement. 70 In transsexual men, administration of an anti-androgen and estrogen, before surgery for gender reassignment, decreased anger and aggression, sexual arousability, and spatial skills and increased verbal fluency. Conversely, testosterone administration to women decreased verbal fluency and increased spatial skills. 71, 72 In summary, the reported literature on testosterone and cognition is equivocal, but these inconsistencies should not be interpreted to mean that there is no effect. Prospective randomized placebo-controlled, trials are needed to determine the effects of physiological testosterone replacement on cognitive function in older women.
TESTOSTERONE AND BONE MINERAL DENSITY
Androgens regulate bone mineral density (BMD) and fracture risk via multiple mechanisms. Testosterone inhibits bone resorption through its conversion to estradiol. 73, 74 In addition, androgens also directly stimulate cortical osteoblastic bone formation. Androgen receptors have been reported on osteoblasts and osteocytes. In addition to effects that are mediated through the nuclear androgen receptors, androgens may also exert nongenomic effects on osteoblasts. Androgens directly stimulate alkaline phosphatase and type-1-␣ collagen synthesis by osteoblasts. In addition, they may indirectly regulate osteoblastic activity by modulating the activity of other bone growth regulators such as IGF-1, IGF-2, fibroblast growth factor, and transforming growth factor-␣ . IGF-1, and insulin-like growth factor binding proteins (IGF-BPs) have important effects on osteoblast proliferation and differentiation. Androgens increase the expression of IGF-1, IGF-BP2, and IGF-BP3 but decrease inhibitory IGF-BP4 in an androgen-responsive human osteoblastic cell line. 75 Testosterone inhibits parathyroid hormone and interleukin-6 (IL-6) activity; these effects might indirectly result in decreased osteoclastogenesis. 76, 77 In men, androgen deficiency is associated with osteoporosis. Androgen replacement in hypogonadal men decreases markers of bone resorption and increases markers of osteoblastic bone formation and cortical bone mass, 78 but the role of androgen deficiency in the pathophysiology of osteoporosis in older women is poorly understood. We do not know whether age-related decline in testosterone contributes to the risk of osteoporosis and fractures in older women. Serum levels of bioavailable testosterone correlate positively with bone mineral density and negatively with N-telopeptide excretion. 79, 80 Women with syndromes of androgen excess have higher bone mass than controls.
Raisz et al. 81 compared the effects of conjugated equine estrogen (CEE) alone with a combined regimen of CEE plus 2.5 mg methyl testosterone on markers of bone formation and bone resorption. Compared with CEE alone, methyl testosterone plus CEE produced a greater increase in bone formation markers such as osteocalcin and bone-specific alkaline phosphatase, but the markers of bone resorption, such as hydroxyproline and pyridinoline crosslinks, were not significantly different between the two groups (Table 4) .
Davis et al. 42 reported greater increases in BMD in the spine and hip with estrogen plus testosterone implants than with estrogen implants alone. In another study of postmenopausal women, Watts et al. 82 also found that testosterone plus CEE treatment increased BMD, but CEE alone did not. Both of these important studies had small sample sizes and were relatively short. The effects of androgen supplementation on fracture risks in women have not been examined. It is possible that testosterone supplementation might augment muscle mass and quadriceps muscle strength in older women with low testosterone levels. Because quadriceps muscle strength is a major determinant of fall propensity, direct effects of testosterone on the muscle might provide an additional mechanism by which testosterone might reduce fracture risk in older women (Table 4) .
Long-term placebo-controlled studies are needed to determine whether testosterone replacement reduces fracture risk in older women. Because the reference of comparison will likely be women receiving HRT, these studies will likely require large sample sizes.
TESTOSTERONE AND IMMUNE FUNCTION
Testosterone regulates several important aspects of immune function. The prevalence of autoimmune diseases is generally higher in women than in men. 83 Decreased levels of androgens were observed in women with systemic lupus erythematosus (SLE), with lower levels correlated to higher disease activity. 83, 84 In an animal model of lupus, the development of "lupus-like" syndrome and progression of kidney disease is more rapid in female than male mice. 85, 86 In this animal model, castration of males is associated with a more accelerated development of lupus-like syndrome, and testosterone administration to females retards the progression of this syndrome. 87, 88 It has been noted that DHEA inhibits IL-6, tumor necrosis factor, and other cytokines by inhibiting nuclear factor-B, activation of which is associated with worsened disease activity. 89 Many patients with autoimmune diseases receive glucocorticoids that might cause loss of muscle and bone mass. Theoretically, testosterone administration, in addition to its immunomodulatory effect, might also prevent or reverse the glucocorticoid-induced muscle wasting and osteoporosis in these patients, but the data on the effects of testosterone administration in patients with autoimmune diseases are not clear. Although some trials of androgen administration failed to demonstrate benefits in patients with rheumatoid arthritis or SLE, 90, 91 other studies have reported improvements in some intermediate outcomes and disease activity scores. [92] [93] [94] [95] In one study, DHEA administration facilitated withdrawal from glucocorticoid therapy in patients with SLE. 94 Whether DHEA can ameliorate the deleterious effects of glucocorticoids on muscles, bones, and endothelium remains to be determined in randomized clinical trials. 96 
ADVERSE EFFECTS ASSOCIATED WITH ANDROGEN REPLACEMENT
The potential deleterious effects of androgen supplementation in women include the risks of virilization, hirsutism, acne, voice change, erythrocytosis, alterations in plasma lipids and apolipoproteins, and liver toxicity. 97, 98 Abnormalities of liver enzymes have been reported with orally administered, 17-␣ alkylated androgens. Hirsutism is uncommon if supraphysiological levels are avoided. 42, 81, [99] [100] [101] There is concern regarding the increase in cardiovascular risk through lowering of high-density lipoprotein (HDL) levels in women receiving long-term androgen therapy. Davis et al. 42 found no significant change in HDL cholesterol levels in women treated with combined estrogen and testosterone implants, although there was a reduction in total cholesterol and low-density lipoprotein (LDL) cholesterol levels. In another study, combined administration of estrogen and 17-␣-methyl testosterone resulted in a 25% reduction in total cholesterol and a modest decrease in HDL2 and HDL3 levels. 81 Some 102, 103 but not all studies 44, 104 have shown DHEA treatment in women to have negative effects on lipids and lipoproteins. It is unclear whether these adverse effects on plasma lipid profile are limited to supraphysiologic doses of androgens or whether physiologic; testosterone replacement can be administered without significant adverse effects on cardiovascular risk factors.
Hyperandrogenemia is associated with insulin resistance in adolescent girls and women with polycystic ovary syndrome (PCOS). 105, 106 Endothelial dysfunction, associated with elevated levels of androgens, may lead to increased risk of macrovascular complications, 105 but consistent correlation between insulin resistance and hyperandrogenemia has not been found in all studies. 106, 107 It is unclear whether insulin resistance in patients with PCOS is due to high androgen levels or is inherited as an independent trait. It has been speculated that androgen effects on insulin sensitivity might be biphasic. Holmang et al. 108 demonstrated that, in a rat model, physiological doses of testosterone improve insulin sensitivity, whereas higher doses induce insulin resistance. 109, 110 A recent epidemiological study found an inverse correlation between serum testosterone concentrations and carotid intima-media thickness, a measure of generalized atherosclerosis. 111, 112 In LDL-receptor-deficient mice, testosterone administration retards the development of early atherosclerotic lesions. Therefore, it remains unclear whether physiological testosterone replacement in older women will increase or decrease the risk of atherosclerotic heart disease.
METHODS OF ANDROGEN ADMINISTRATION
An oral formulation of testosterone, 17-␣-methyltestosterone, approved for use in women in the United States, is typically administered orally in combination with estrogens in doses between 1.25 and 2.5 mg daily. It may be associated with liver toxicity. 97, 98 Other formulations that have been empirically used in women include testosterone esters, testosterone pellets, and testosterone undecenoate given orally in oleic acid (not available in the United States). Testosterone esters, enanthate and cypionate, and the androgenic steroid, nandrolone decanoate, are used traditionally at doses of 25 to 50 mg every 4 weeks, but this regimen may lead to supraphysiological androgen concentrations in the first few days after the injection and suboptimal levels during the last 10 days of the dosing interval. Testosterone implants, administered at a dose of 50 mg every 4 to 6 months, have been used widely outside the United States, but, because of the need for skin incision and insertion through a trocar and the small incidence of spontaneous extrusion, the implants have not been popular in the United States. Oral micronized DHEA at a dose of 25 to 50 mg daily has also been used in clinical trials, but there is considerable batch-to-batch and brand-to-brand variability in the amount of DHEA in various formulations sold over the counter. In addition, the absorption of DHEA from the gastrointestinal tract is variable, and its efficacy in postmenopausal women in improving health-related outcomes has not been established. It should be emphasized that only limited amounts of pharmacokinetic data are available Greater increase in bone mineral density with combined treatment than with estrogen alone about these formulations in women, and the regimens used in clinical practice have generally not been physiological. Two novel testosterone formulations, specifically for use in women, are currently in development. A transdermal testosterone matrix patch has been designed for twice weekly application to the skin. Each transdermal testosterone matrix system (TMTDS) nominally delivers 150 g of testosterone per day. Thus, two patches applied twice a week can deliver 300 g of testosterone daily, approximating the daily production rates of testosterone in healthy menstruating women. The pharmacokinetics of transdermally administered testosterone have been studied in premenopausal women, surgically menopausal women, and HIV-infected women. 30, 113 These studies have demonstrated that a regimen of two TMTDS patches applied twice a week can maintain serum total and free testosterone levels in the upper-normal range, respectively, in pre-and postmenopausal women with low testosterone levels. Application of each TMTDS patch increases serum total testosterone concentrations on average by 20 to 25 ng/dL. 113 The increments in serum total and free testosterone levels are lower in HIV-infected women treated with TMTDS than healthy women, presumably because of increased plasma clearance or decreased absorption. The skin tolerability of the TMTDS patch has been excellent, with only a small proportion of treated women experiencing mild erythema at the patch application site.
A 1% hydro-alcoholic testosterone gel is under development for use in women; its potential advantages include ease of delivery, invisibility after application, and good skin tolerability. We postulate that testosterone patches and gels will be the most widely used forms of androgen replacement for women in the future, leading to high patient satisfaction and the ability to tolerate dosing to achieve testosterone concentrations in the upper-normal range.
CONCLUSION
Because of the limited availability of sensitive and accurate assays for the measurement of total and free testosterone levels in women and the paucity of normative data, it has been difficult to biochemically define androgen deficiency in women. Although there is tremendous interest in exploring the clinical applications of testosterone supplementation in older women for a number of clinical indications, we do not know whether physiological testosterone replacement can improve clinically relevant outcomes such as physical function, muscle mass and performance, fracture risk, cognitive function, and sexual function. The long-term risks of virilizing side effects and cardiovascular disease also remain largely unknown. Therefore, it would be premature to make a general recommendation about testosterone replacement for all older women with low testosterone levels. At this time, testosterone supplementation in women with the symptom complex that has been loosely named "female androgen deficiency syndrome" should be individualized and preceded by a discussion about the uncertainty of beneficial effects and the potential risks of long-term androgen administration. Further studies are needed to establish testosterone doseresponse relationships in women to determine whether it is possible to dissociate the clinically beneficial effects from potential adverse effects.
